article · ACS Materials Au
High Resolution Image Download MS PowerPoint Slide LNPs are the basis of mRNA and nucleic acid-based therapeutics. However, their remarkable clinical potential is limited by a persistent challenge, i.e., nonspecific accumulation in the liver and associated hepatotoxicity. Traditional strategies, such as PEGylation and lipid ionization modification, have reached a point of low therapeutic value-add to control biodistribution. Recently published studies present an innovative concept: LNPs that recruit albumin, exploiting interactions with endogenous albumin to avoid liver accumulation and simultaneously improve delivery through the lymphatic system for immune-modulation. This review provides a concise incursion into such strategies that redefine stealth nanomedicine, not as chemical camouflage but as a biological alliance with plasma transport proteins, paving the way for a new paradigm of self-protecting nanocarriers for safer and more precise mRNA therapeutics.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1021/acsmaterialsau.6c00068
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
